[PDF] Top 20 LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
Has 10000 "LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD" found on our website. Below are the top 20 most common "LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD".
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
... (current/ex-smoker), COPD exacerbation history (yes/no), baseline ICS use (yes/no), and region as fixed effects; baseline FEV 1 measurement and FEV 1 revers- ibility as covariates; and center nested within region ... See full document
12
Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
... this study should be interpreted in the context of its ...current study, such adjustment is imperfect and does not obviate the need for further assessment in cohorts bal- anced with respect to baseline ... See full document
9
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
... to salmeterol therapy seen in this study, which occurred despite higher FSC drug costs, provide important information for ...this study, however, FSC was associated with significantly lower ... See full document
9
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
... 6-week study in patients with moderate COPD dem- onstrated that the LAMA tiotropium (18 mcg once daily) in combination with the LABA formoterol (12 mcg twice daily), delivered via separate ... See full document
12
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
... FLAME study, IND/ GLY 110/50 µ g ...severe COPD exacerbations, improved lung function, and improved health status versus SFC in the Asian cohort when compared with the total FLAME ...from ... See full document
11
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
... The study comprised a prescreening visit, a 14-day screen- ing/run-in period, and five single-dose treatment ...visit, patients’ ongoing COPD medications were reviewed and, if necessary, any pro- ... See full document
8
The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
... fixed-dose combination therapy of an inhaled corticosteroid (ICS)/long-acting ...in COPD. Real-world observational studies have shown that combination therapy has significantly greater odds of ... See full document
10
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
... female patients aged $40 years, with a clinical diagnosis of moderate- to-severe COPD (Stage II or III) according to the GOLD strategy (ILLUMINATE; GOLD 2009 and LANTERN; GOLD ...2010). ... See full document
9
Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE
... Akihiro Kobayashi and Tomoyuki Hayamizu were employees of GSK at the time of the study conduct with no other relationships or activities that could appear to have influenced the submitted work. Takefumi Saito ... See full document
12
COPD: maximization of bronchodilation
... studies QVA149 was well tolerated over the 26 and 52 -week study, re- spectively, with an adverse events profile similar to that of placebo (Table ...the combination compared with the single ... See full document
10
When is dual bronchodilation indicated in COPD?
... Relevant medical literature on long-acting bronchodi- lator monotherapy, dual bronchodilation, and/or inhaled corticosteroids (ICSs) plus long-acting β 2 -agonists (LABAs) was identified by searching the PubMed (Medline) ... See full document
15
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
... Binary mortality data: total number of deaths (r) from (n) subjects, and hazard ratios with reported confidence intervals from published studies meeting our inclusion criteria were used as inputs to the analysis. We ... See full document
13
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
... Este estudio se diseñó por tanto para comparar el comienzo de acción de dosis únicas de 150 y 300 µg de indacaterol con el de salbutamol, salmeterol-fluticasona y placebo. El estudio se realizó como estaba ... See full document
8
Comparison of heat sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial
... and water and how Essence-Qi is infused into the three hundred and sixty-five joints. That is why the disease of the Five Zang-Organs are manifested over the twelve Yuan-Primary acupoints which show cer- tain ... See full document
9
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
... For D2, we replaced FEV 1 with TDI, and did so to have a definition of CID composed solely of “clinical” endpoints rather than lung function. This definition appeared to be less sensitive than D1, and there was greater ... See full document
13
Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
... censored. Patients were deemed to be censored or lost to follow-up when they discontinued receiving their index therapy (defined as a gap in therapy greater than 90 days between ...prescriptions). Patients’ ... See full document
10
A Study on Budesonide/ Formoterol vs. Fluticasone/ Salmeterol Inhaled Combination in Moderate to Severe Asthma
... excluded: COPD, current or ex-smokers (≥10 packs/ year); severe asthma exacerbation or symptomatic infec- tion of the airways in the previous 8 weeks; ≥3 courses of oral corticosteroids or hospitalization due to ... See full document
6
Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
... population-based study, we compared the effects of budesonide/formoterol and fluticasone/salmeterol on the occurrence of severe exacerbation and pneumonia in propensity score-matched COPD ... See full document
9
The lung function profile of once-daily tiotropium and olodaterol via Respimat<sup>®</sup> is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler<sup>®</sup> (ENERGITO<sup>®</sup> study)<div><br /></div>
... moderate-to-severe COPD who require maintenance treatment with the goal of improving lung function, with associated symptomatic and health-status benefits, tiotropium + olodaterol should be considered as another ... See full document
13
Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
... ICS/LABA combination therapies are well established, it is also important to con- sider the specific components of the combination in order to optimize levels of patient ...ICS fluticasone propionate ... See full document
10
Related subjects